PUBLISHER: The Business Research Company | PRODUCT CODE: 1664755
PUBLISHER: The Business Research Company | PRODUCT CODE: 1664755
Therapeutic BCG Vaccines Global Market Report 2025
The therapeutic BCG vaccine is designed to provide protection against tuberculosis (TB). Not included in the standard NHS vaccination schedule, this vaccine, also known as Bacillus Calmette-Guerin vaccine, is administered as a single dose throughout a person's lifetime.
There main types of therapeutic BCG vaccines such as therapy BCG and immune BCG. Therapy BCG is an intravesical immunotherapy specifically targeting early-stage bladder cancer by bolstering the immune system to target and eliminate cancer cells. This vaccine can be administered to both pediatric and adult populations and finds applications in hospitals, clinics, and various other healthcare settings.
The therapeutic BCG vaccines market research report is one of a series of new reports from The Business Research Company that provides therapeutic BCG vaccines market statistics, including therapeutic BCG vaccines industry global market size, regional shares, competitors with a therapeutic BCG vaccines market share, detailed therapeutic BCG vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic BCG vaccines industry. This therapeutic BCG vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $56.47 billion in 2024 to $59.66 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to government initiatives for tb control, immune system modulation, global immunization programs, treatment of bladder cancer, investments in vaccine manufacturing, emergence of drug-resistant tb strains.
The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $77.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion to other indications, increased research on immunotherapy, global efforts against emerging infectious diseases, regulatory support for vaccine development, focus on tuberculosis elimination. Major trends in the forecast period include advancements in vaccine technology, supply chain optimization, market consolidation and partnerships, patient education and awareness, alternative delivery methods, personalized medicine approaches.
The growing number of tuberculosis (TB) cases worldwide is expected to drive the expansion of the therapeutic BCG vaccine market in the coming years. Tuberculosis is a potentially serious infectious disease that mainly affects the lungs. It spreads through the air when people cough or sneeze, releasing small droplets of bacteria. BCG vaccines are designed to boost the immune system's ability to fight infection but do not cause TB, as the bacteria used in the vaccine are weakened. The vaccine consistently provides protection against the most severe forms of TB, such as adolescent TB meningitis. By protecting against tuberculosis, the BCG vaccine helps combat infection, leading to increased use of therapeutic BCG vaccines. For example, in February 2024, a report from the UK Health Security Agency, a government body in the UK, revealed that TB cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. As a result, the rising incidence of tuberculosis globally is fueling the growth of the therapeutic BCG vaccine market.
The increasing prevalence of drug-resistant tuberculosis (DR-TB) cases is poised to drive the expansion of the therapeutic BCG vaccine market in the coming years. Drug-resistant TB occurs when Mycobacterium tuberculosis, the causative bacteria, develops resistance to standard medications used for treatment. While therapeutic Bacillus Calmette-Guerin (BCG) vaccines are primarily recognized for preventing specific forms of TB, their potential application in addressing drug-resistant tuberculosis has gained attention. For example, as of November 2023, the Centers for Disease Control and Prevention reported that 8.4% of TB cases in the United States in 2022 exhibited resistance to at least isoniazid, including 1.4% with multidrug resistance. Within the U.S.-born population, 5.7% had isoniazid-resistant TB, with 0.7% classified as multidrug-resistant TB. The increasing incidence of drug-resistant TB cases is thus a key factor driving the therapeutic BCG vaccine market.
Strategic partnerships have become a prominent trend gaining traction in the therapeutic BCG vaccine market. Leading companies in this market are focusing on collaborating with other key players to maintain their market position. For example, in May 2024, ImmunityBio, a US-based biotechnology company, partnered with Serum Institute of India, an India-based biotechnology and biopharmaceutical company, to secure a supply of the Bacillus Calmette-Guerin (BCG) vaccine for all cancer types. The partnership aims to produce the standard BCG (sBCG) approved for use outside the US, along with a next-generation recombinant BCG (iBCG), which is currently undergoing testing. The iBCG is intended to be used alongside ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-PMLN) for approved and future indications, pending regulatory approvals.
Major players in the therapeutic BCG vaccine market are directing their efforts towards vaccine innovation for diverse therapeutic applications, such as BCG immunotherapy, to broaden their customer base and address expanding patient needs. BCG immunotherapy involves utilizing the BCG vaccine for immunotherapeutic purposes, particularly in treating certain types of cancer, such as bladder cancer. In a noteworthy development in July 2023, The Serum Institute of India, a biotechnology and biopharmaceuticals company, received government approval to export its BCG vaccine to Canada for immunotherapeutic use in bladder cancer treatment. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette-Guerin), is administered intravenously in 40 mg and 80 mg presentations. The targeted administration directly into the bladder aims to impact cancer cells effectively while minimizing effects on other parts of the body, exemplifying the industry's focus on therapeutic innovation and strategic collaborations.
In February 2022, Sanofi S.A., a France-based multinational pharmaceutical and healthcare corporation, acquired Amunix for an undisclosed sum. This strategic acquisition grants Sanofi access to Amunix's innovative Pro-XTEN, XPAT, and XPAC technologies, facilitating the delivery of conditionally activated biologics representing the next phase in biopharmaceutical innovation. These technological advancements are expected to bolster Sanofi's efforts in advancing and diversifying its portfolio of advanced therapies, particularly in the field of oncology. With approximately 20 compounds currently in the developmental pipeline, this acquisition aligns seamlessly with Sanofi's existing research and development initiatives. Amunix, headquartered in the United States, specializes in immuno-oncology and is dedicated to the discovery, design, and development of novel biologics, proteins, and peptide therapeutics.
Major companies operating in the therapeutic bcg vaccines market include Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Cipla Limited, Instituto Butantan
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the therapeutic bcg vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The therapeutic BCG vaccines market consists of sales of vectors, peptides, proteins, DNA, and dendritic cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Therapeutic BCG Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on therapeutic bcg vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for therapeutic bcg vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The therapeutic bcg vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Therapy BCG; Immune BCG
- 2) By Demographics: Pediatrics; Adults
- 3) By End Use: Hospitals; Clinics; Other End Users
- Subsegments:
- 1) By Therapy BCG: Intravesical BCG; Injectable BCG
- 2) By Immune BCG: BCG For Immune Enhancement; BCG For Allergy Treatment
- Companies Mentioned: Merck & Co Inc.; Sanofi Pasteur; Japan BCG Laboratory; China National Biotec Group; Serum Institute of India Pvt. Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Therapeutic BCG Vaccines Market Characteristics
3. Therapeutic BCG Vaccines Market Trends And Strategies
4. Therapeutic BCG Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Therapeutic BCG Vaccines Growth Analysis And Strategic Analysis Framework
- 5.1. Global Therapeutic BCG Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Therapeutic BCG Vaccines Market Growth Rate Analysis
- 5.4. Global Therapeutic BCG Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Therapeutic BCG Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Therapeutic BCG Vaccines Total Addressable Market (TAM)
6. Therapeutic BCG Vaccines Market Segmentation
- 6.1. Global Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Therapy BCG
- Immune BCG
- 6.2. Global Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pediatrics
- Adults
- 6.3. Global Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Other End Users
- 6.4. Global Therapeutic BCG Vaccines Market, Sub-Segmentation Of Therapy BCG, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravesical BCG
- Injectable BCG
- 6.5. Global Therapeutic BCG Vaccines Market, Sub-Segmentation Of Immune BCG, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- BCG For Immune Enhancement
- BCG For Allergy Treatment
7. Therapeutic BCG Vaccines Market Regional And Country Analysis
- 7.1. Global Therapeutic BCG Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Therapeutic BCG Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Therapeutic BCG Vaccines Market
- 8.1. Asia-Pacific Therapeutic BCG Vaccines Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Therapeutic BCG Vaccines Market
- 9.1. China Therapeutic BCG Vaccines Market Overview
- 9.2. China Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Therapeutic BCG Vaccines Market
- 10.1. India Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Therapeutic BCG Vaccines Market
- 11.1. Japan Therapeutic BCG Vaccines Market Overview
- 11.2. Japan Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Therapeutic BCG Vaccines Market
- 12.1. Australia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Therapeutic BCG Vaccines Market
- 13.1. Indonesia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Therapeutic BCG Vaccines Market
- 14.1. South Korea Therapeutic BCG Vaccines Market Overview
- 14.2. South Korea Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Therapeutic BCG Vaccines Market
- 15.1. Western Europe Therapeutic BCG Vaccines Market Overview
- 15.2. Western Europe Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Therapeutic BCG Vaccines Market
- 16.1. UK Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Therapeutic BCG Vaccines Market
- 17.1. Germany Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Therapeutic BCG Vaccines Market
- 18.1. France Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Therapeutic BCG Vaccines Market
- 19.1. Italy Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Therapeutic BCG Vaccines Market
- 20.1. Spain Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Therapeutic BCG Vaccines Market
- 21.1. Eastern Europe Therapeutic BCG Vaccines Market Overview
- 21.2. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Therapeutic BCG Vaccines Market
- 22.1. Russia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Therapeutic BCG Vaccines Market
- 23.1. North America Therapeutic BCG Vaccines Market Overview
- 23.2. North America Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Therapeutic BCG Vaccines Market
- 24.1. USA Therapeutic BCG Vaccines Market Overview
- 24.2. USA Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Therapeutic BCG Vaccines Market
- 25.1. Canada Therapeutic BCG Vaccines Market Overview
- 25.2. Canada Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Therapeutic BCG Vaccines Market
- 26.1. South America Therapeutic BCG Vaccines Market Overview
- 26.2. South America Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Therapeutic BCG Vaccines Market
- 27.1. Brazil Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Therapeutic BCG Vaccines Market
- 28.1. Middle East Therapeutic BCG Vaccines Market Overview
- 28.2. Middle East Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Therapeutic BCG Vaccines Market
- 29.1. Africa Therapeutic BCG Vaccines Market Overview
- 29.2. Africa Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Therapeutic BCG Vaccines Market Competitive Landscape And Company Profiles
- 30.1. Therapeutic BCG Vaccines Market Competitive Landscape
- 30.2. Therapeutic BCG Vaccines Market Company Profiles
- 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Japan BCG Laboratory Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. China National Biotec Group Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Therapeutic BCG Vaccines Market Other Major And Innovative Companies
- 31.1. InterVax Ltd.
- 31.2. GreenSignal Bio Pharma Limited
- 31.3. Statens Serum Institute
- 31.4. AJ Vaccines
- 31.5. Bul Bio-National Center of Infectious and Parasitic Diseases Ltd
- 31.6. Biomed Lublin S.A.
- 31.7. Microgen
- 31.8. Taj Pharma Ltd.
- 31.9. PT Bio Farma
- 31.10. Torlak Institute of Virology
- 31.11. Bacille Bilie Calmette-Guerin Laboratory
- 31.12. China Biotechnology Co Ltd.
- 31.13. Bharat Biotech International Ltd.
- 31.14. Biological E. Limited
- 31.15. Shanghai Institute of Biological Products Co. Ltd.
32. Global Therapeutic BCG Vaccines Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Therapeutic BCG Vaccines Market
34. Recent Developments In The Therapeutic BCG Vaccines Market
35. Therapeutic BCG Vaccines Market High Potential Countries, Segments and Strategies
- 35.1 Therapeutic BCG Vaccines Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Therapeutic BCG Vaccines Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Therapeutic BCG Vaccines Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
